代谢相关脂肪性肝病(metabolic-associated fatty liver disease, MAFLD)原名非酒精性脂肪肝(non-alcoholic fatty liver disease, NAFLD),被认为是代谢综合征的肝脏表现,已成为发达国家和发展中国家最常见的慢性肝病,预计患病率在未来几年仍会有所上升,是终末期肝脏疾病、肝癌和肝移植的主要原因,影响着全球人口的1/3。结直肠癌(colorectal cancer, CRC)通过腺瘤–癌序列发展,是全球发病率第三、死亡率第二的恶性肿瘤。研究表明,MAFLD与总体癌症发病率增加相关,肿瘤是MAFLD患者第二大常见死因。既往已有多项研究发现NAFLD与结直肠肿瘤(colorectal neoplasia, CRN)存在相关性,但鉴于MAFLD与NAFLD诊断标准存在差异,MAFLD与CRN的相关性应得到进一步探索,本文旨在对MAFLD与CRN相关性进行综述,进而为CRN的预防与治疗提供新思路。Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is considered as the liver manifestation of metabolic syndrome. It has become the most common chronic liver disease in both developed and developing countries, with prevalence expected to increase in the coming years, and is the leading cause of end-stage liver disease, liver cancer, and liver transplantation, affecting one-third of the global population. Colorectal cancer (CRC) develops through the adenomato-cancer sequence, and is the third most common malignant tumor in the world with the second highest mortality rate. Studies have shown that MAFLD is associated with an increased incidence of cancer overall, and tumors are the second most common cause of death in people with MAFLD. Many studies have found a correlation between NAFLD and colorectal neoplasia (CRN). However, due to differences in diagnostic criteria between MAFLD and NAFLD, the correlation between MAFLD and CRN should be further explored. This article aims to review the correlation between MAFLD and CRN, so as to provide new ideas for the preventio
